Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Change in Receivables (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Change in Receivables for 16 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 251.82% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.9 million, a 54.08% decrease, with the full-year FY2025 number at $2.9 million, down 54.08% from a year prior.
  • Change in Receivables was $1.5 million for Q4 2025 at Lemaitre Vascular, up from -$3.9 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $5.8 million in Q1 2024 to a low of -$3.9 million in Q3 2025.
  • A 5-year average of $842550.0 and a median of $800000.0 in 2021 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: skyrocketed 357.0% in 2022, then crashed 513.59% in 2025.
  • Lemaitre Vascular's Change in Receivables stood at $393000.0 in 2021, then surged by 357.0% to $1.8 million in 2022, then tumbled by 41.09% to $1.1 million in 2023, then plummeted by 196.12% to -$1.0 million in 2024, then skyrocketed by 251.82% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for LMAT's Change in Receivables are $1.5 million (Q4 2025), -$3.9 million (Q3 2025), and $680000.0 (Q2 2025).